Award
Purchase Order #75N98026P01474
Contract for Metabolomic Analysis of Phenylbutyrate in ME/CFS Patients
Buyer
National Institutes of Health
Award Amount
$41,400.00
Ceiling
$41,400.00
Awarded
September 30, 2026
Period of Performance
Sep 30, 2026 – Sep 29, 2027
Identifier
75N98026P01474
NAICS
621511
This purchase order contract was awarded to Metabolon, Inc., a company specializing in metabolomic profiling and data analysis, to conduct a detailed study on the effects of phenylbutyrate treatment in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The contract facilitates a focused metabolomic analysis aimed at understanding biochemical changes induced by the therapy, which is significant for advancing treatment research in this challenging chronic illness. The scope includes conducting metabolomic assays and analyzing patient samples to elucidate biochemical pathways affected by phenylbutyrate. This contract was competitively acquired as a purchase order, reflecting its targeted, research-driven nature. The performance period spans one year, covering study execution and data reporting. The award contributes valuable scientific insights with potential therapeutic implications for the medical community addressing ME/CFS.
Description
METABOLOMIC ANALYSIS OF THE EFFECTS OF PHENYLBUTYRATE (PB) IN PATIENTS WITH MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS)